The End of Transplant for Mantle Cell Lymphoma

January 31, 2025
Speakers: Brian Hill, MD, PhD, and Tim Fenske, MD

In this episode, Contributing Editor Brian Hill, MD, PhD, director of the lymphoid malignancies program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, talks with Tim Fenske, MD, who at the time of this recording was joining the transplant and cell therapy group at Sara Cannon Methodist Healthcare in San Antonio, Texas. Dr. Fenske previously led the lymphoma program at the Medical College of Wisconsin. They talk about a new study that found a lack of benefit in autologous stem cell transplantation for patients with mantle cell lymphoma.

DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

December 21, 2024
Speakers: Ajai Chari, MD, Meletios Dimopoulos, MD

In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Meletios Dimopoulos, MD, a professor and chair of the Department of Clinical Therapeutics at the National and Kopodistrian University of Athens School of Medicine in Athens, Greece. They talk about a recent paper co-authored by Dr. Dimopoulos: “Belantamab Mafodotin, Pomalidomide (PA), and Dexamethasone in Multiple Myeloma.”

Haploidentical Stem Cell Transplantation Is an Acceptable Transformative Therapy for Young Adults With Sickle Cell Disease

November 27, 2024
Speakers: Samuel Wilson, MD, and Adetola Kassim, MD

In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina Chapel Hill, talks with Adetola Kassim, MD, a professor of medicine in the division of hematology and oncology at Vanderbilt University Medical Center. They talk about a recent paper co-authored by Dr. Kassim: “An International Learning Collaborative Phase 2 Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease.”